Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
Ayisha Sharma / endpoints - Biogen and Denali Therapeutics’ LRRK2 inhibitor has flunked a Phase 2b trial in early Parkinson’s disease, leading the companies to drop the program in certain patients. The small-molecule drug, known as BIIB122, missed the study’s ...
AI Summary: After disappointing mid‑stage results, developers have stopped advancement of a candidate Parkinson’s therapy for non‑genetic forms of the disease. The setback underscores the challenges of translating promising mechanisms into clinical benefit and will force sponsors to reassess pipelines and patient selection strategies.
Related Stories
Drug-induced hibernation shows promise to limit stroke brain injury / 21 days
Gene therapy pioneers win Breakthrough Prize for CRISPR sickle‑cell work / 2 months
First-in-human trial primes immune system to accept donor livers / 2 months
Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 2 months
Keratin 16 restrains skin inflammation and may guide treatments / 3 months
Avalyn upsizes IPO to raise cash for lung drug trials / 2 months
New science pushes erectile disorder treatment beyond Viagra / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Mergers and Acquisitions, Healthcare, Neuroscience, CDC and look for the RSS link.
StackHealth Time Machine